Heated Tobacco vs Vaping: How Nicotine Delivery Is Evolving

Combustible cigarettes are losing market share to three alternatives simultaneously. Heated tobacco products, e-cigarettes, and nicotine pouches each deliver nicotine through a completely different mechanism. For manufacturers and ingredient suppliers, this fragmentation is the defining reality of the modern nicotine industry.

One supplier portfolio. Three different product specs. Three different regulatory regimes.

The numbers tell the story. Global combustible cigarette volumes have declined roughly 2% per year since 2020, while alternative nicotine products have grown at double-digit rates. Philip Morris International reported that its smoke-free products accounted for over 38% of net revenue in 2025. BAT's "New Categories" segment crossed GBP 4 billion. JTI's reduced-risk portfolio continues expanding in Asia and Europe. The money is moving, and the supply chain has to move with it.

Heated Tobacco: Combustion's Nearest Neighbor

Heated tobacco products (HTPs) use specially designed tobacco sticks heated to 250-350 degrees C. That is well below the 600-900 degrees C where combustion happens in a traditional cigarette. The result: nicotine and flavor release without tar and many of the harmful compounds that combustion generates.

The major players:

• IQOS (Philip Morris International). Market leader with over 30 million users globally. Blade-based heating system with HEETS/TEREA tobacco sticks.
• glo (BAT). Induction heating with Neostiks. Strong presence in Japan, Korea, and parts of Europe.
• Ploom (JTI). Redesigned induction heating platform gaining traction in Japan and Italy.
• lil (KT&G). South Korea's domestic champion, now expanding internationally.

Japan remains the largest HTP market by a wide margin, accounting for roughly 40% of global heated tobacco sales. The Japanese government's classification of HTPs under existing tobacco tax frameworks (rather than imposing new regulatory categories) gave the format a head start there that other markets have not replicated.

Where nicotine suppliers fit: HTPs primarily use processed tobacco, not extracted nicotine. But that is changing. Next-generation HTP designs increasingly use nicotine-enriched substrates and reconstituted tobacco sheets with added nicotine to hit target delivery levels. PMI's LEVIA product, which uses a tobacco-free nicotine substrate, signals where this category is heading. When HTPs move beyond tobacco leaf, they need pharmaceutical-grade nicotine alkaloid or high-purity freebase nicotine as a raw material. This is a growing segment for extracted nicotine suppliers and one that demands tight purity documentation.

The technical challenge is consistency. Reconstituted sheets need uniform nicotine distribution to deliver predictable pharmacokinetics. Suppliers serving this segment need to provide detailed certificates of analysis, batch-to-batch consistency data, and often custom concentration specifications.

Vaping: The Extracted Nicotine Market

Vaping devices heat e-liquid (nicotine dissolved in VG/PG carriers with flavorings) into an inhalable aerosol. No tobacco leaf involved. The nicotine is extracted, purified, and dissolved. This is the segment where extracted nicotine suppliers have historically done the most volume.

Three hardware segments, three trajectories:

• Open systems (refillable tanks and mods). Declining in most regulated markets due to tightening restrictions. Still significant in parts of Asia and among enthusiast communities.
• Closed systems/pods (JUUL, VUSE, IQOS VEEV, etc.). The dominant format in regulated markets. Manufacturers control the full supply chain from ingredient to finished good.
• Disposables. Fastest growing in terms of unit sales, but facing regulatory crackdowns globally. The EU's revised TPD is expected to restrict or ban single-use vapes. The UK implemented its disposable ban in June 2025. Australia has moved to a prescription-only model.

The disposable crackdown is reshaping procurement. As markets close to disposables, volume shifts to closed pod systems and (in some regions) back to open systems. For nicotine ingredient suppliers, this changes order patterns. Disposable manufacturers tend to place large, infrequent bulk orders. Pod system manufacturers run more consistent, specification-driven procurement cycles with stricter quality requirements.

Nicotine requirements are specific. E-liquid manufacturing needs high-purity extracted nicotine in precise forms:

• Freebase nicotine at USP/EP grade (99.5%+ purity) for traditional e-liquids. Understanding what USP/EP grade actually means matters here, because not every supplier claiming pharmacopoeial grade can back it up with proper documentation.
• Nicotine salts (benzoate, lactate, tartrate, or other salt forms) for pod systems and higher-concentration formulations. Salt-based e-liquids now dominate the closed-system market because they deliver higher nicotine concentrations with less throat irritation.
• Pre-mixed nicotine dilutions in VG/PG carriers, typically at 100 mg/mL. The choice between VG and PG as a carrier has real consequences for viscosity, flavor interaction, and device compatibility.

The carrier choice alone changes your production process, flavor profile, and target device compatibility. VG-based dilutions produce thicker vapor and smoother throat hit. PG-based dilutions carry flavor more effectively and work better in lower-power devices. Most manufacturers need both on hand, and some need custom ratios.

One underappreciated trend: nicotine concentration standardization. The EU TPD caps e-liquid at 20 mg/mL. The UK follows the same limit. But other markets allow higher concentrations (50 mg/mL is common in the US and parts of Asia). Manufacturers serving multiple geographies need ingredient suppliers who can deliver nicotine at different concentrations and in different salt forms, all with the regulatory documentation appropriate to each destination market.

Nicotine Pouches: The Fastest Segment

No heating element. No liquid. No tobacco leaf. Just a small white pouch between the lip and gum delivering nicotine through oral mucosal absorption.

The global pouch market is projected to reach $35 billion by 2028. Swedish Match (now owned by PMI) pioneered the modern format with ZYN, which alone generated over $3 billion in US revenue in 2025. Competitors have piled in. BAT's VELO, Turning Point Brands' FRE, Kretek International's NIIN, and dozens of smaller players are all fighting for shelf space.

Consumer adoption is driven by a simple value proposition: discreet, smoke-free, spit-free nicotine that can be used anywhere. Regulators have generally been more receptive to a product with no combustion, no inhalation, and no tobacco leaf. The US FDA granted modified risk tobacco product (MRTP) authorization for General Snus in 2019, and the regulatory environment for tobacco-free pouches remains more favorable than for vaping in most jurisdictions.

Nicotine requirements are different again:

• Nicotine bitartrate dihydrate. The dominant form for pouches. Solid at room temperature, water-soluble, and stable in storage. It allows precise milligram dosing in manufacturing, which is critical when your product label says "6 mg" and regulators will test to verify. The technical advantages of bitartrate over other forms for oral products are well documented.
• Nicotine polacrilex. An ion-exchange resin complex used in controlled-release applications. This is the same form used in nicotine gum (Nicorette and generics). Pouch manufacturers targeting pharmaceutical or quasi-pharmaceutical positioning use polacrilex for its established regulatory history.
• Freebase nicotine. Used in some higher-strength formulations, though less common in pouches due to stability and dosing precision challenges.

The manufacturing process for nicotine pouches is more similar to food or pharmaceutical production than to tobacco manufacturing. Pouch producers need ingredient suppliers who understand GMP environments, provide certificates of analysis that meet pharmaceutical standards, and can deliver consistent batch quality. A guide on choosing your nicotine supplier is worth reviewing if you are evaluating options for pouch production.

Three Formats, One Supply Chain Problem

Here is what the fragmentation means in practice:

Product portfolio breadth

A decade ago, most extracted nicotine demand was for e-liquid. Today, a supplier needs to serve e-liquid manufacturers, pouch producers, pharmaceutical NRT companies, and increasingly HTP customers. Each one has different product specs. Different concentration requirements. Different documentation standards.

NicAlliance is one of the suppliers that has built a portfolio spanning all these segments, from pure nicotine and salts to bitartrate and polacrilex. But portfolio breadth alone is not enough. The real question is whether a supplier can deliver each product with the documentation and quality assurance specific to its end use.

Quality standards are converging upward

Even non-pharmaceutical products now routinely require pharmacopoeial-grade nicotine. This is not manufacturers being cautious. It is regulators and retail buyers raising the floor. The gap between "pharmaceutical grade" and "everything else" is closing because everything else is being pulled up to pharmaceutical standards.

The FDA's PMTA process has been a major driver in the US. Even though PMTAs apply to finished products, the FDA expects detailed characterization of every ingredient, including nicotine source, purity, impurity profiles, and supplier quality systems. Manufacturers who sourced nicotine from unverified suppliers have found their PMTA submissions rejected or delayed. The risks of working with unverified suppliers are not hypothetical; they show up as regulatory delays, product recalls, and lost market access.

In Europe, TPD compliance requires emissions testing, ingredient notification, and toxicological data. The nicotine ingredient supplier's documentation feeds directly into those submissions. ISO, HACCP, and GMP certifications are table stakes, not differentiators.

Regulatory complexity multiplies

HTPs face tobacco product regulation in most markets. Vapes face TPD in Europe, PMTA in the US, and varying frameworks elsewhere. Pouches face novel food regulations in some markets and tobacco-adjacent regulation in others. A country-by-country regulatory guide is practically required reading for anyone selling into multiple geographies.

Your nicotine supplier needs to understand these distinctions because the documentation they provide feeds directly into your regulatory filings. A certificate of analysis formatted for EU TPD notification looks different from one supporting a US PMTA. A supplier who provides a single generic COA for all markets is creating work for your regulatory team (or worse, creating risk).

Traceability has become a competitive requirement, not just a nice-to-have. Regulators increasingly want to see chain of custody from tobacco field through extraction, purification, and delivery. STC certification and similar programs exist specifically to provide this kind of verified traceability.

New forms, new opportunity

The evolution is not over. Novel nicotine salts, encapsulated nicotine, slow-release formulations, and nicotine-enriched substrates are all in active development. Manufacturers with supplier relationships that include R&D collaboration will move faster than those treating nicotine as a commodity purchase.

Oral nicotine products beyond pouches are emerging. Nicotine toothpicks, lozenges, gummies, and dissolving strips are all in various stages of development or market launch. Each format has its own release kinetics, stability requirements, and regulatory pathway. The common thread is that all of them need precisely characterized, pharmaceutical-quality nicotine as a starting ingredient.

Ethical sourcing and ESG considerations are also becoming procurement criteria, particularly for publicly traded manufacturers and those selling into European markets. Supply chain transparency is no longer optional for companies that answer to institutional investors or face EU due diligence regulations.

What This Means for Procurement

Few manufacturers today source nicotine for a single product format in a single market. The trend is toward multi-format portfolios sold across multiple regulatory jurisdictions.

That reality puts pressure on the supplier relationship. You need a supplier who can deliver freebase nicotine for your e-liquid line, bitartrate for your pouch line, and polacrilex for your NRT products, all at pharmacopoeial grade with documentation tailored to each destination market.

The alternative is managing three or four supplier relationships, each with its own qualification process, audit schedule, and supply risk profile. Some manufacturers do this deliberately for supply security. For many others, it is an unintentional result of outgrowing a supplier who only serves one segment.

The nicotine delivery landscape will keep fragmenting. The manufacturers who navigate this successfully will be those with supply chain foundations flexible enough to support whatever comes next.

Frequently Asked Questions